Yibai Pharmaceutical: Azacitidine for Injection Obtained Drug Registration Certificate.

On March 27, Yibai Pharmaceutical announced that the company has recently received the "Drug Registration Certificate" for the injection of Azacytidine issued by the National Medical Products Administration. The injection of Azacytidine is used for the treatment of intermediate-2 and high-risk myelodysplastic syndromes in the International Prognostic Scoring System; chronic myelomonocytic leukemia; acute myeloid leukemia classified by the World Health Organization with 20%-30% bone marrow blasts and multilineage dysplasia in adult patients.